These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 28318420)

  • 1. Bayesian penalized log-likelihood ratio approach for dose response clinical trial studies.
    Tang Y; Cai C; Sun L; He J
    J Biopharm Stat; 2017; 27(6):975-989. PubMed ID: 28318420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design considerations and analysis planning of a phase 2a proof of concept study in rheumatoid arthritis in the presence of possible non-monotonicity.
    Liu F; Walters SJ; Julious SA
    BMC Med Res Methodol; 2017 Oct; 17(1):149. PubMed ID: 28969588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypothesis testing and Bayesian estimation using a sigmoid Emax model applied to sparse dose-response designs.
    Thomas N
    J Biopharm Stat; 2006; 16(5):657-77. PubMed ID: 17037264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bayesian adaptive patient enrollment restriction to identify a sensitive subpopulation using a continuous biomarker in a randomized phase 2 trial.
    Ohwada S; Morita S
    Pharm Stat; 2016 Sep; 15(5):420-9. PubMed ID: 27485377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bayesian dose-finding in phase I/II clinical trials using toxicity and efficacy odds ratios.
    Yin G; Li Y; Ji Y
    Biometrics; 2006 Sep; 62(3):777-84. PubMed ID: 16984320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bayesian designs of phase II oncology trials to select maximum effective dose assuming monotonic dose-response relationship.
    Guo B; Li Y
    BMC Med Res Methodol; 2014 Jul; 14():95. PubMed ID: 25074481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A mixture model using likelihood-based and Bayesian approaches for identifying responders and non-responders in longitudinal clinical trials.
    He J; Entsuah R
    Pharm Stat; 2014; 13(5):327-36. PubMed ID: 25182571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An extension of Bayesian predictive sample size selection designs for monitoring efficacy and safety.
    Teramukai S; Daimon T; Zohar S
    Stat Med; 2015 Sep; 34(22):3029-39. PubMed ID: 26038148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A robust Bayesian dose-finding design for phase I/II clinical trials.
    Liu S; Johnson VE
    Biostatistics; 2016 Apr; 17(2):249-63. PubMed ID: 26486139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bayesian design of single-arm phase II clinical trials with continuous monitoring.
    Johnson VE; Cook JD
    Clin Trials; 2009 Jun; 6(3):217-26. PubMed ID: 19528131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bayesian approach to two-stage phase II trial.
    Pepple PA; Choi SC
    J Biopharm Stat; 1997 May; 7(2):271-86. PubMed ID: 9136069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continual reassessment method: a likelihood approach.
    O'Quigley J; Shen LZ
    Biometrics; 1996 Jun; 52(2):673-84. PubMed ID: 8672707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bayesian dose-finding designs for combination of molecularly targeted agents assuming partial stochastic ordering.
    Guo B; Li Y
    Stat Med; 2015 Feb; 34(5):859-75. PubMed ID: 25413162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of predictive probabilities in phase II and phase III clinical trials.
    Johns D; Andersen JS
    J Biopharm Stat; 1999 Mar; 9(1):67-79. PubMed ID: 10091910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adaptive designs for dose-finding in non-cancer phase II trials: influence of early unexpected outcomes.
    Resche-Rigon M; Zohar S; Chevret S
    Clin Trials; 2008; 5(6):595-606. PubMed ID: 19029208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Likelihood ratio and a Bayesian approach were superior to standard noninferiority analysis when the noninferiority margin varied with the control event rate.
    Kim MY; Xue X
    J Clin Epidemiol; 2004 Dec; 57(12):1253-61. PubMed ID: 15617951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A flexible Bayesian approach for modeling monotonic dose-response relationships in drug development trials.
    Ohlssen D; Racine A
    J Biopharm Stat; 2015; 25(1):137-56. PubMed ID: 24836192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Bayesian approach to jointly modeling toxicity and biomarker expression in a phase I/II dose-finding trial.
    Bekele BN; Shen Y
    Biometrics; 2005 Jun; 61(2):343-54. PubMed ID: 16011680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Practical guidelines for adaptive seamless phase II/III clinical trials that use Bayesian methods.
    Kimani PK; Glimm E; Maurer W; Hutton JL; Stallard N
    Stat Med; 2012 Aug; 31(19):2068-85. PubMed ID: 22437262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ASTIN: a Bayesian adaptive dose-response trial in acute stroke.
    Grieve AP; Krams M
    Clin Trials; 2005; 2(4):340-51; discussion 352-8, 364-78. PubMed ID: 16281432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.